Cargando…
PB1935: CARDIOTOXICITY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITORS: A REVIEW OF REAL-WORLD OBSERVATIONAL EVIDENCE
Autores principales: | Balijepalli, Chakrapani, Siliman, Gaye, Joshy, Juhi, Gullapalli, Lakshmi, Druyts, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429817/ http://dx.doi.org/10.1097/01.HS9.0000974560.08770.66 |
Ejemplares similares
-
PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Shi, Wenyu
Publicado: (2023) -
PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023) -
PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023) -
PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
por: Cassanello, G., et al.
Publicado: (2022) -
Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes
por: Balijepalli, Chakrapani, et al.
Publicado: (2017)